Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial - The Lancet
Patients Shed 15% of Body Weight With Tirzepatide, Drugmaker Says | MedPage Today
Vasso's Corner: Tirzepatide, a new era for dual-treatment for type-2 diabetes and obesity - Neos Kosmos
Developments in diabetes management: What do we know about tirzepatide? - Hospital News
Blood sugar drug tirzepatide also leads to substantial weight loss in diabetes patients, Eli Lilly says | CNN
Type 2 Diabetes Treatment to Lower A1C | Mounjaro® (tirzepatide)
Tirzepatide (Mounjaro): A Q&A With the ADA's Dr. Robert Gabbay | Everyday Health
Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial -
Dr. Karl Nadolsky - In people with type 2 #diabetes and elevated cardiovascular risk, tirzepatide, compared with glargine, demonstrated greater and clinically meaningful HbA1c reduction with a lower incidence of hypoglycaemia at
December Blog Post: Tirzepatide, Worth the Weight?
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | NEJM
Tirzepatide Delivers in SURMOUNT-2 - Cardiac Wire
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | NEJM
Why Lilly's tirzepatide has blockbuster potential - Drug Discovery and Development
Effect of tirzepatide on glycaemic control captured with continuous glucose monitoring in patients with type 2 diabetes (SURPASS-3 CGM) - Media Centre | EASD
Mounjaro (tirzepatide) for the Treatment of Type 2 Diabetes, USA
Late-Stage Trial Results Show Promise for Eli Lilly's Tirzepatide as Treatment for Type 2 Diabetes | BioSpace
Lilly eyes weight loss arena for diabetes drug tirzepatide after positive data - Pharmaceutical Technology
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | NEJM
First GLP-1/GIP Receptor Agonist OK'd for Type 2 Diabetes | MedPage Today
Type 2 Diabetes Drug Tirzepatide (Mounjaro) Aids Weight Loss in People With Obesity: Study | Everyday Health
SURPASS-2: A Study Of Tirzepatide Versus Semaglutide Once Weekly As Add-on Therapy To Metformin In Participants With Type 2 Diabetes - My Endo Consult
Tirzepatide Slowed Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes with Increased Cardiovascular Risk | ADA
Tirzepatide for diabetes: on track to SURPASS current therapy | Nature Medicine
Tirzepatide reduces appetite, energy intake and fat mass in people with type 2 diabetes - Media Centre | EASD
Mounjaro: New Tirzepatide diabetes jab that sparked diabetes row in US could get approved on NHS | The Independent
FDA approves tirzepatide, Eli Lilly's new type 2 diabetes drug, and the company shares an estimated price
